Trump’s Malaria Drug Fails Another Trial On Covid-19 Patients

'Dotun Akintomide
Writer

Ad

[Video] Sowore Raises Alarm, Says Security Forces Fired Live Bullets, Nnamdi Kanu’s Brother ‘Beaten and Arrested’ During Protest

Human rights activist and politician Omoyele Sowore has accused security operatives of an "unprovoked attack" on peaceful demonstrators in Abuja on Monday. This is as Sowore claimed that live bullets were fired at the group and that the younger brother and lawyer of the detained leader of the Indigenous People of Biafra (IPOB), Nnamdi Kanu,…

Supply and Demand Fears Continue to Drag Oil Prices Lower

Oil prices slipped in early Asian trade on Monday, as a combination of burgeoning supply concerns and escalating U.S.–China trade tensions weighed on sentiment. At the time of writing, Brent crude futures had dropped 0.29% to $61.11 while WTI was down 0.35% at $57.34. The continued drop comes on the heels of a third consecutive weekly decline for both benchmarks,…

Osinbajo Set to Lead ECOWAS Team to Observe Côte d’Ivoire’s Presidential Poll

The Economic Community of West African States (ECOWAS) has tapped former Nigerian Vice President Professor Yemi Osinbajo to spearhead its Election Observation Mission (EOM) for Côte d’Ivoire’s upcoming presidential election. ECOWAS announced the appointment on Sunday, highlighting Osinbajo’s extensive experience in governance and regional diplomacy as key to ensuring a transparent and peaceful process. As…

Ad

U.S. President Donald Trump’s malaria drug which he touted as a “game changer” for coronavirus has again failed to show a benefit in hospitalised patients.

A study published in the New England Journal of Medicine reported that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death.

“We didn’t see any association between getting this medicine and the chance of dying or being intubated,” lead researcher Dr. Neil Schluger told Reuters in a telephone interview.

“The patients who got the drug didn’t seem to do any better.”

Among patients given hydroxychloroquine, 32.3% ended up needing a ventilator or dying, compared with 14.9% of patients who were not given the drug.

But doctors were more likely to give hydroxychloroquine to sicker patients, so researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center adjusted the rates to account for that.

They concluded that the drug may not have hurt patients, but it clearly did not help.

Decades old hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, also showed no benefit when combined with the antibiotic azithromycin, Schluger’s team reported.

Azithromycin alone also showed no benefit.

Last month, doctors at the U.S. Department of Veterans Affairs reported that hydroxychloroquine did not help COVID-19 patients and might pose a higher risk of death.

That analysis of medical records showed a death rate of 28% when the drug was given in addition to standard treatments, compared to 11% with standard care alone.

In the latest study, 811 patients got hydroxychloroquine and 565 did not.

Because they were not randomly assigned to receive hydroxychloroquine or a placebo, “the study should not be taken to rule out either benefit or harm” for the drug, researchers said.

Randomized trials, the gold standard for tests of new therapies, should continue, they added.

But for now, “the guidance in our hospital has changed so we don’t recommend giving hydroxychloroquine to hospitalised patients,” said Dr. Schluger, chief of the division of pulmonary, allergy and critical care medicine at Irving.

Reuters/NAN

Ad

X whatsapp